vs
Bowhead Specialty Holdings Inc.（BOW）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
Bowhead Specialty Holdings Inc.的季度营收约是再鼎医药的1.2倍（$151.7M vs $127.1M），Bowhead Specialty Holdings Inc.自由现金流更多（$326.0M vs $-26.7M）
Bowhead Specialty Holdings Inc.是一家专业保险控股企业，主营财产及意外伤害保险产品，聚焦北美地区服务不足的小众细分市场，为商业和个人客户提供定制化风险管理方案与专属保险保障服务。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
BOW vs ZLAB — 直观对比
营收规模更大
BOW
是对方的1.2倍
$127.1M
自由现金流更多
BOW
多$352.7M
$-26.7M
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $151.7M | $127.1M |
| 净利润 | $14.8M | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | 11.7% | -54.6% |
| 净利率 | 9.8% | — |
| 营收同比 | — | 17.1% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $0.44 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BOWZLAB
| Q4 25 | $151.7M | $127.1M | ||
| Q3 25 | $143.9M | $115.4M | ||
| Q2 25 | $133.3M | $109.1M | ||
| Q1 25 | $122.7M | $105.7M | ||
| Q4 24 | — | $108.5M | ||
| Q3 24 | $116.8M | $101.8M | ||
| Q2 24 | $98.9M | $100.1M | ||
| Q1 24 | — | $87.1M |
净利润BOWZLAB
| Q4 25 | $14.8M | — | ||
| Q3 25 | $15.2M | $-36.0M | ||
| Q2 25 | $12.3M | $-40.7M | ||
| Q1 25 | $11.4M | $-48.4M | ||
| Q4 24 | — | — | ||
| Q3 24 | $12.1M | $-41.7M | ||
| Q2 24 | $5.5M | $-80.3M | ||
| Q1 24 | — | $-53.5M |
毛利率BOWZLAB
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% | ||
| Q1 24 | — | 61.4% |
营业利润率BOWZLAB
| Q4 25 | 11.7% | -54.6% | ||
| Q3 25 | 13.3% | -42.3% | ||
| Q2 25 | 11.9% | -50.3% | ||
| Q1 25 | 11.8% | -53.3% | ||
| Q4 24 | — | -62.6% | ||
| Q3 24 | 13.5% | -66.6% | ||
| Q2 24 | 7.5% | -76.0% | ||
| Q1 24 | — | -80.7% |
净利率BOWZLAB
| Q4 25 | 9.8% | — | ||
| Q3 25 | 10.5% | -31.2% | ||
| Q2 25 | 9.3% | -37.3% | ||
| Q1 25 | 9.3% | -45.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | 10.4% | -40.9% | ||
| Q2 24 | 5.6% | -80.2% | ||
| Q1 24 | — | -61.4% |
每股收益（稀释后）BOWZLAB
| Q4 25 | $0.44 | $-0.05 | ||
| Q3 25 | $0.45 | $-0.03 | ||
| Q2 25 | $0.36 | $-0.04 | ||
| Q1 25 | $0.34 | $-0.04 | ||
| Q4 24 | — | $-0.09 | ||
| Q3 24 | $0.36 | $-0.04 | ||
| Q2 24 | $0.20 | $-0.08 | ||
| Q1 24 | — | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $193.5M | $689.6M |
| 总债务越低越好 | $146.4M | — |
| 股东权益账面价值 | $448.3M | $715.5M |
| 总资产 | $2.4B | $1.2B |
| 负债/权益比越低杠杆越低 | 0.33× | — |
8季度趋势，按日历期对齐
现金及短期投资BOWZLAB
| Q4 25 | $193.5M | $689.6M | ||
| Q3 25 | $197.9M | $717.2M | ||
| Q2 25 | $114.8M | $732.2M | ||
| Q1 25 | $88.0M | $757.3M | ||
| Q4 24 | — | $779.7M | ||
| Q3 24 | $132.9M | $616.1M | ||
| Q2 24 | $180.3M | $630.0M | ||
| Q1 24 | — | $650.8M |
总债务BOWZLAB
| Q4 25 | $146.4M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益BOWZLAB
| Q4 25 | $448.3M | $715.5M | ||
| Q3 25 | $430.2M | $759.9M | ||
| Q2 25 | $407.2M | $791.7M | ||
| Q1 25 | $391.0M | $810.8M | ||
| Q4 24 | — | $840.9M | ||
| Q3 24 | $364.7M | $667.7M | ||
| Q2 24 | $339.9M | $704.2M | ||
| Q1 24 | — | $762.2M |
总资产BOWZLAB
| Q4 25 | $2.4B | $1.2B | ||
| Q3 25 | $2.1B | $1.2B | ||
| Q2 25 | $1.9B | $1.2B | ||
| Q1 25 | $1.8B | $1.2B | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | $1.5B | $985.3M | ||
| Q2 24 | $1.4B | $987.4M | ||
| Q1 24 | — | $988.4M |
负债/权益比BOWZLAB
| Q4 25 | 0.33× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $331.6M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $326.0M | $-26.7M |
| 自由现金流率自由现金流/营收 | 214.9% | -21.0% |
| 资本支出强度资本支出/营收 | 3.7% | 0.5% |
| 现金转化率经营现金流/净利润 | 22.34× | — |
| 过去12个月自由现金流最近4个季度 | $593.4M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流BOWZLAB
| Q4 25 | $331.6M | $-26.0M | ||
| Q3 25 | $114.7M | $-32.0M | ||
| Q2 25 | $109.0M | $-31.0M | ||
| Q1 25 | $47.7M | $-61.7M | ||
| Q4 24 | — | $-55.8M | ||
| Q3 24 | $119.4M | $-26.8M | ||
| Q2 24 | — | $-42.2M | ||
| Q1 24 | — | $-90.1M |
自由现金流BOWZLAB
| Q4 25 | $326.0M | $-26.7M | ||
| Q3 25 | $113.5M | $-35.0M | ||
| Q2 25 | $107.4M | $-33.9M | ||
| Q1 25 | $46.5M | $-63.2M | ||
| Q4 24 | — | $-58.4M | ||
| Q3 24 | $118.4M | $-28.2M | ||
| Q2 24 | — | $-42.9M | ||
| Q1 24 | — | $-91.1M |
自由现金流率BOWZLAB
| Q4 25 | 214.9% | -21.0% | ||
| Q3 25 | 78.8% | -30.4% | ||
| Q2 25 | 80.6% | -31.1% | ||
| Q1 25 | 37.9% | -59.9% | ||
| Q4 24 | — | -53.8% | ||
| Q3 24 | 101.4% | -27.7% | ||
| Q2 24 | — | -42.9% | ||
| Q1 24 | — | -104.5% |
资本支出强度BOWZLAB
| Q4 25 | 3.7% | 0.5% | ||
| Q3 25 | 0.9% | 2.6% | ||
| Q2 25 | 1.2% | 2.6% | ||
| Q1 25 | 1.0% | 1.5% | ||
| Q4 24 | — | 2.4% | ||
| Q3 24 | 0.9% | 1.3% | ||
| Q2 24 | — | 0.7% | ||
| Q1 24 | — | 1.1% |
现金转化率BOWZLAB
| Q4 25 | 22.34× | — | ||
| Q3 25 | 7.56× | — | ||
| Q2 25 | 8.83× | — | ||
| Q1 25 | 4.18× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 9.88× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BOW
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
